Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Danny Rischin*, Michael R. Migden, Annette M. Lim, Chrysalyne D. Schmults, Nikhil I. Khushalani, Brett G.M. Hughes, Dirk Schadendorf, Lara A. Dunn, Leonel Hernandez-Aya, Anne Lynn S. Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Thomas Eigentler, Brian Stein, Anna C. Pavlick, Jessica L. Geiger, Ralf Gutzmer, Murad Alam, Emmanuel OkoyeMelissa Mathias, Vladimir Jankovic, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Israel Lowy, Matthew G. Fury, Alexander Guminski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing'. Together they form a unique fingerprint.

Medicine & Life Sciences